Low Bone Mineral Density in Early Pubertal Transgender/Gender Diverse Youth: Findings From the Trans Youth Care Study

Janet Y. Lee,1,2 Courtney Finlayson,3 Johanna Olson-Kennedy,4 Robert Garofalo,5 Yee-Ming Chan,6 David V. Glidden,7 and Stephen M. Rosenthal1

1Division of Pediatric Endocrinology, Department of Pediatrics, University of California, San Francisco, San Francisco, California 94143; 2Division of Endocrinology and Metabolism, Department of Medicine, University of California, San Francisco, San Francisco, California 94143; 3Division of Endocrinology, Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611; 4Division of Adolescent and Young Adult Medicine, Department of Pediatrics, Keck School of Medicine of University of Southern California, Los Angeles, California 90027; 5Division of Adolescent Medicine, Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611; 6Division of Endocrinology, Department of Pediatrics, Boston Children’s Hospital, Boston, Massachusetts 02115; and 7Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California 94143

ORCiD numbers: 0000-0002-3563-8843 (J. Y. Lee); 0000-0001-9704-4525 (C. Finlayson); 0000-0001-6264-7596 (J. Olson-Kennedy); 0000-0001-9513-9416 (R. Garofalo); 0000-0003-0554-8502 (Y.-M. Chan); 0000-0001-5888-1419 (D. V. Glidden); 0000-0001-5027-1464 (S. M. Rosenthal).

Context: Transgender youth may initiate GnRH agonists (GnRHa) to suppress puberty, a critical period for bone-mass accrual. Low bone mineral density (BMD) has been reported in late-pubertal transgender girls before gender-affirming therapy, but little is known about BMD in early-pubertal transgender youth.

Objective: To describe BMD in early-pubertal transgender youth.

Design: Cross-sectional analysis of the prospective, observational, longitudinal Trans Youth Care Study cohort.

Setting: Four multidisciplinary academic pediatric gender centers in the United States.

Participants: Early-pubertal transgender youth initiating GnRHa.

Main Outcome Measures: Areal and volumetric BMD Z-scores.

Results: Designated males at birth (DMAB) had below-average BMD Z-scores when compared with male reference standards, and designated females at birth (DFAB) had below-average BMD Z-scores when compared with female reference standards except at hip sites. At least 1 BMD Z-score was < -2 in 30% of DMAB and 13% of DFAB. Youth with low BMD scored lower on the Physical Activity Questionnaire for Older Children than youth with normal BMD, 2.32 ± 0.71 vs. 2.76 ± 0.61 (P = 0.01). There were no significant deficiencies in vitamin D, but dietary calcium intake was suboptimal in all youth.

Conclusions: In early-pubertal transgender youth, BMD was lower than reference standards for sex designated at birth. This lower BMD may be explained, in part, by suboptimal calcium intake and decreased physical activity—potential targets for intervention. Our results suggest a potential need for assessment of BMD in prepubertal gender-diverse youth and continued monitoring of BMD throughout the pubertal period of gender-affirming therapy.

Abbreviations: aBMD, areal bone mineral density; BMD, bone mineral density; DFAB, designated female at birth; DMAB, designated male at birth; DXA, dual-energy X-ray absorptiometry; GAH, gender-affirming hormone therapy; GnRHa, GnRH agonist; PAQ-C, Physical Activity Questionnaire for Older Children; QCT, quantitative computed tomography; TBLH, total body less head; TGD, transgender and gender-diverse; TH, total hip; vBMD, volumetric bone mineral density.
An estimated 0.7% to 2.7% of American teenagers identify as transgender or gender nonconforming [1-3], and gender-affirming hormone therapy (GAH) for transgender and gender-diverse (TGD) youth in the United States has been provided for more than a decade [4]. Since then, access to pediatric GAH has rapidly expanded, with many prominent academic institutions establishing multidisciplinary clinics, often in partnership with community centers [5]. For youth who meet diagnostic criteria for gender dysphoria [6], current guidelines recommend GnRH agonists (GnRHa) to pause puberty as early as Tanner stage 2 to prevent physical changes inconsistent with the affirmed gender and to allow additional time for gender exploration [7, 8]. Little is known, however, about bone mineral density (BMD) or long-term consequences of early pubertal suppression on skeletal health in these youth.

Data from the Netherlands have shown that pretreatment BMD Z-scores determined by dual-energy X-ray absorptiometry (DXA) were significantly low in late-pubertal transgender girls before GnRHa and failed to normalize upon treatment with estradiol [9, 10]. Adult studies have similarly shown low BMD Z-scores in transgender women before and after GAH [11-13]. A UK study showed late-pubertal transgender boys had lower pretreatment BMD Z-scores by DXA at the spine and hip [14]. In contrast, another Dutch study that focused on transgender boys in late or postpuberty (median age, 16.5 years) showed normal mean pretreatment BMD Z-scores by DXA at the spine and hip [15]. Little is known, however, about BMD in early-pubertal transgender youth or about factors that impact skeletal health in this population, such as dietary calcium intake, vitamin D status, and weight-bearing exercise. Based on the low BMD Z-scores observed in the previously noted studies in late-pubertal adolescents and adults, further investigation of transgender youth in earlier stages of puberty is needed to determine when this disparity in BMD emerges.

We present pretreatment BMD data from our multisite cohort of 63 American TGD youth initiating puberty suppression in early puberty. Selected determinants of bone health were also examined to identify potential targets for intervention.

1. Materials and Methods

TGD youth, defined as those whose gender identity is atypical of the sex designated at birth, nonbinary, or fluid [16], were prospectively enrolled from 4 study sites (Children’s Hospital Los Angeles, Lurie Children’s Hospital, Boston Children’s Hospital, and University of California San Francisco Benioff Children’s Hospital) in the observational Trans Youth Care Study as previously described [17]. Eligible participants in this cohort were at Tanner stages 2-3 (based on breast or testicular examination) and initiating pubertal blockade with GnRHa. Primary outcomes were areal BMD (aBMD) and volumetric BMD (vBMD) Z-scores assessed by DXA and quantitative computed tomography (QCT), respectively. BMD was assessed before or no more than 2 months after the puberty blocker was initiated. Of the 95 participants in the puberty-blocker cohort, 13 were excluded because no DXA or QCT was performed, 13 were excluded because they were at Tanner stage 4 of puberty, and 6 were excluded because DXA was assessed more than 2 months after puberty blocker initiation. After these 32 participants were excluded, a total of 63 participants were included in the data analyses. More than 90% (57/63) of included participants had BMD assessed before initiation of GnRHa.
Because of the observational nature of this study, methods and machines used for assessment of BMD varied among the study sites. At Children’s Hospital Los Angeles, cortical and trabecular vBMD were assessed by QCT at midshaft femur and L1-L3 vertebral bodies, respectively [18]. Lurie Children’s Hospital used a GE/Lunar iDXA machine with scans of total body less head (TBLH) and lumbar spine. Boston Children’s Hospital and University of California San Francisco Benioff Children’s Hospital used Hologic Discovery A DXA machines with scans of TBLH, lumbar spine, and/or total hip (TH) and femoral neck. Because of insurance coverage considerations, 17% (11/63) of participants obtained their DXA scans from outside institutions. Pretreatment BMD Z-scores were analyzed according to the sex designated at birth, and adjustments according to height Z-scores were calculated for Hologic DXA scans to allow data comparison across sites [19]. Because of the significant differences in imaging modalities and body sites evaluated, aBMD and vBMD Z-scores were analyzed separately. After separate analyses of Lunar BMD Z-scores and height-adjusted Hologic BMD Z-scores yielded similar results [20], we pooled aBMD Z-score results. Serum 25-hydroxyvitamin D was measured by standard clinical assays, dietary calcium intake was assessed with a 1-week food inventory questionnaire, and physical activity was assessed with the Physical Activity Questionnaire for Older Children (PAQ-C) [21, 22], which rates physical activity for a variety of activities on a Likert scale (1 = lowest activity, 5 = highest activity).

All data analyses were performed using Stata, v16 (College Station, TX) [23] and were stratified by sex designated at birth or by whether low BMD was present, as defined by at least 1 BMD Z-score < -2. Comparisons between groups were performed using Student t tests. After verifying the assumption of normally distributed residuals and assessing departure from linearity, a linear regression model was used to determine whether chosen predictors were statistically significant predictors of BMD Z-scores. We set a significance level of $\alpha = 0.05$ for all statistical analyses. Participant characteristics were compared among the 4 sites using ANOVA and did not exhibit statistically significant differences by site [20]; participants from all sites were therefore grouped for analyses.

2. Results

A. Demographics

Demographics of the cohort show essentially balanced sex designated at birth, majority white race (56%), majority total household income greater than $100 000 (75%), and majority of guardians/parents having completed undergraduate or graduate/professional degrees (68%) (Table 1). The majority of the participants reported a binary gender identity (92%), and 64% of the participants were in Tanner stage 2 of puberty. Differences in age at time of puberty blocker initiation between designated females at birth (DFAB) and designated males at birth (DMAB) reflect the expected pubertal timing of sex designated at birth, 11.0 ± 1.4 years vs. 12.1 ± 1.3 years ($P = 0.002$).

B. Primary BMD outcomes

A low aBMD or vBMD Z-score, defined as < -2, was observed in 30% (10/33, 95% confidence interval [CI], 15.6-48.7) of DMAB and 13% (4/30, 95% CI, 3.8-30.7) of DFAB, significantly higher rates than the 2.3% expected in a normal distribution (Fig. 1). When reviewing the subset of participants with low BMD, 25-hydroxyvitamin D levels were 28.7 ± 10.8 ng/mL, daily calcium intake was 520 ± 383 mg/d, PAQ-C scores were 2.32 ± 0.71, and BMI Z-scores were 0.08 ± 1.57. The average age at initiation of puberty blocker initiation between designated females at birth (DFAB) and designated males at birth (DMAB) reflect the expected pubertal timing of sex designated at birth, 11.0 ± 1.4 years vs. 12.1 ± 1.3 years ($P = 0.002$).
normal BMD group, the low BMD group had statistically significantly lower PAQ-C scores, 2.32 ± 0.71 vs. 2.76 ± 0.61 (P = 0.01).

Both aBMD and vBMD Z-scores (Figs. 2 and 3) revealed mean BMD Z-scores consistently lower in DMAB than in DFAB, with a statistically significant difference at the hip sites, which primarily reflect measurements of cortical bone.

C. Selected determinants of bone health

Review of the selected determinants of bone health by sex designated at birth showed that 15% (5 DMAB and 3 DFAB, 8/53 of TGD youth who had serum 25-hydroxyvitamin D measured) had vitamin D insufficiency (<20 ng/mL). Notably, the daily calcium intake of all TGD youth was suboptimal with mean 613 ± 345 mg daily, far below the recommended 1300 mg per day [24, 25]. Although these recommended dietary allowance values for calcium intake may be considered ambitious, prior literature based on National Health and Nutrition Examination Study data from 2003 to 2006 reported that 9- to 13-year-old children consumed approximately 1000 mg of calcium per day [26]. There were no statistically significant differences based on sex designated at birth in serum 25-hydroxyvitamin D, daily calcium intake, or BMI Z-scores (Table 3).
There were statistically significant differences in PAQ-C physical-activity scores between DFAB and DMAB, with DFAB reporting higher activity scores than DMAB, 2.83 ± 0.57 vs. 2.50 ± 0.69 (P = 0.04) (Table 3). For reference, the original validation studies of the

---

**Table 2.** Selected Determinants of Bone Health, by Low<sup>a</sup> vs. Normal BMD

<table>
<thead>
<tr>
<th></th>
<th>Low BMD Group (n = 14)</th>
<th>Normal BMD Group (n = 49)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at blocker placement, years, mean ± SD (95% CI)</td>
<td>12.0 ± 1.7 (11.1-13.0)</td>
<td>11.5 ± 1.4 (11.1-11.8)</td>
<td>0.9</td>
</tr>
<tr>
<td>Tanner stage, mean ± SD (95% CI)</td>
<td>2.43 ± 0.50 (2.25-2.62)</td>
<td>2.30 ± 0.47 (2.14-2.47)</td>
<td>0.3</td>
</tr>
<tr>
<td>PAQ-C score, (1 = low, 5 = high), mean ± SD (95% CI)</td>
<td>2.32 ± 0.71 (1.91-2.73)</td>
<td>2.76 ± 0.61 (2.58-2.93)</td>
<td>0.01</td>
</tr>
<tr>
<td>Serum 25-hydroxyvitamin D, ng/mL, mean ± SD (95% CI)</td>
<td>28.7 ± 10.8 (21.0-36.4)</td>
<td>28.8 ± 9.3 (26.0-31.7)</td>
<td>0.5</td>
</tr>
<tr>
<td>Daily calcium intake, mg/day, mean ± SD (95% CI)</td>
<td>520 ± 106 (289-752)</td>
<td>637 ± 334 (541-733)</td>
<td>0.1</td>
</tr>
<tr>
<td>BMI Z-score, mean ± SD (95% CI)</td>
<td>0.08 ± 1.57 (-0.83 to 0.99)</td>
<td>0.40 ± 0.99 (0.12-0.68)</td>
<td>0.2</td>
</tr>
<tr>
<td>Height Z-score, mean ± SD (95% CI)</td>
<td>-0.27 ± 1.02 (-0.86 to 0.32)</td>
<td>0.22 ± 1.12 (-0.10 to 0.54)</td>
<td>0.07</td>
</tr>
</tbody>
</table>

<sup>a</sup>At least 1 BMD Z-score < -2.

Abbreviations: BMD, bone mineral density; BMI, body mass index; CI, confidence interval; PAQ-C, Physical Activity Questionnaire for Older Children.
PAQ-C in 1997 examined scores in 125 boys and 90 girls ages 9 to 15 years, in whom gender identity was not assessed, and showed mean PAQ-C physical-activity scores of 3.44 ± 0.68 for boys and 2.96 ± 0.69 for girls [21]. A more recent Canadian school-based assessment of 643 fifth graders, also without specific assessment of gender identity, showed mean PAQ-C physical-activity scores of 3.36 ± 0.72 for boys and 3.21 ± 0.72 for girls [27]. Given the population studies regarding prevalence of TGD individuals, we assume that the aforementioned studies [21, 27] primarily describe cis-gender youth.
D. Significant predictors of BMD Z-scores

Using a conceptual framework of determinants of BMD and bone health as previously described [28], a multivariate linear regression analysis was performed to evaluate for significant variables contributing to BMD Z-scores. The following predictors were included in the linear regression model: sex designated at birth, PAQ-C score, BMI Z-score, Tanner stage, age at puberty blocker placement, dietary calcium intake, and serum 25-hydroxyvitamin D (Table 4). BMI Z-scores were positive contributors to BMD Z-scores at the TBLH site \((P < 0.0001)\). Female sex designated at birth \((P = 0.04)\) and serum 25-hydroxyvitamin D \((P = 0.048)\) were positive predictors and age at puberty blocker placement \((P = 0.049)\) was a negative predictor of TH BMD Z-scores. Age at puberty blocker placement \((P = 0.02)\) was a negative predictor of femoral neck BMD...
Z-scores. No predictors reached statistical significance for the trabecular and cortical vBMD Z-scores.

In summary, female sex designated at birth and higher serum 25-hydroxyvitamin D were associated with higher TH BMD Z-scores, and later age at puberty blocker placement was associated with lower BMD Z-scores at the DXA hip sites. At the TBLH site, higher BMI Z-scores were associated with higher BMD Z-scores.

### 3. Discussion

We identified a high prevalence of low BMD (Z-score < -2) in early-pubertal TGD youth before starting GnRHa therapy, with higher rates in DMAB than in DFAB. Our findings extend prior studies in late-pubertal transgender youth [9], by demonstrating that low BMD is already present by early puberty and thus this disparity could arise before puberty. Earlier identification of low BMD in prepubertal TGD youth could therefore expand the time for potential interventions to mitigate this pretreatment discordance in BMD and, in turn, the expected further decrease in BMD Z-scores with GnRHa [9, 10, 14, 15]. Our linear regression results support this concept because age at puberty blocker placement was negatively associated with BMD Z-scores at the hip sites, suggesting that underlying factors contributing to low BMD may potentially have more time to exert negative effects. This negative association can also be explained, in part, by the differential timing of puberty in DMAB versus DFAB individuals, as DMAB youth had both lower BMD Z-scores and later ages at pubertal onset. Additionally, because eligibility was based on early-pubertal status, older individuals in the study cohort started puberty at the later end of the usual age range, so it is expected that they would have lower BMD compared with reference ranges based on youth who largely had more typical timing of puberty and thus had significant exposure to sex steroids by that age. Contribution of Tanner stage at time of blocker initiation to BMD Z-scores was not statistically significant at any anatomical sites, but the mostly positive β-coefficients in our regression models suggest that later Tanner stage at time of puberty blocker placement had a positive effect on BMD Z-scores, reflecting the positive effect of pubertal hormones on bone mineralization.

We additionally noted that there were statistically significant differences in BMD Z-scores at the hip sites between DMAB and DFAB groups. Although the International Society for Clinical Densitometry notes that the hip is not a preferred site for pediatric DXA measurements [29], the hip is primarily cortical bone, whereas the lumbar spine is primarily

### Table 3. Selected Determinants of Bone Health, by Sex Designated at Birth

<table>
<thead>
<tr>
<th></th>
<th>Designated Females at Birth</th>
<th>Designated Males at Birth</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at blocker placement, years, mean ± SD (95% CI)</td>
<td>11.0 ± 1.4 (10.5-11.5)</td>
<td>12.1 ± 1.3 (11.7-12.6)</td>
<td>0.002</td>
</tr>
<tr>
<td>Tanner stage, mean ± SD (95% CI)</td>
<td>2.43 ± 0.50 (2.25-2.62)</td>
<td>2.30 ± 0.47 (2.14-2.47)</td>
<td>0.3</td>
</tr>
<tr>
<td>PAQ-C score, (1 = low, 5 = high), mean ± SD (95% CI)</td>
<td>2.83 ± 0.57 (2.63-3.04)</td>
<td>2.50 ± 0.69 (2.26-2.74)</td>
<td>0.04</td>
</tr>
<tr>
<td>Serum 25-hydroxyvitamin D, ng/mL, mean ± SD (95% CI)</td>
<td>30.8 ± 7.3 (28.0-33.7)</td>
<td>26.9 ± 11.0 (22.6-31.1)</td>
<td>0.1</td>
</tr>
<tr>
<td>Daily calcium intake, mg/day, mean ± SD (95% CI)</td>
<td>540 ± 269 (441-640)</td>
<td>676 ± 393 (540-813)</td>
<td>0.1</td>
</tr>
<tr>
<td>BMI Z-score, mean ± SD (95% CI)</td>
<td>0.28 ± 1.05 (-0.11 to 0.67)</td>
<td>0.38 ± 1.22 (-0.06 to 0.81)</td>
<td>0.7</td>
</tr>
<tr>
<td>Height Z-score, mean ± SD (95% CI)</td>
<td>-0.03 ± 1.17 (-0.46 to 0.39)</td>
<td>0.25 ± 1.05 (-0.12 to 0.61)</td>
<td>0.3</td>
</tr>
</tbody>
</table>

**Abbreviations:** BMD, bone mineral density; BMI, body mass index; CI, confidence interval; PAQ-C, Physical Activity Questionnaire for Older Children.
Table 4. Predictors of BMD Z-scores: Multivariate Linear Regression Models

<table>
<thead>
<tr>
<th>Predictors of aBMD Z-scores</th>
<th>TBLH</th>
<th></th>
<th>LS</th>
<th></th>
<th>TH</th>
<th></th>
<th>FN</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>(Constant)</td>
<td>-2.1</td>
<td>-6.6 to 2.5</td>
<td>0.4</td>
<td>-0.5</td>
<td>-6.1 to 5.1</td>
<td>0.9</td>
<td>3.6</td>
<td>-3.1 to 10.3</td>
</tr>
<tr>
<td>Female sex designated at birth</td>
<td>0.4</td>
<td>-0.3 to 1.0</td>
<td>0.3</td>
<td>0.07</td>
<td>-0.7 to 0.9</td>
<td>0.9</td>
<td>0.9</td>
<td>0.03 to 1.7</td>
</tr>
<tr>
<td>PAQ-C score</td>
<td>0.3</td>
<td>-0.3 to 0.9</td>
<td>0.3</td>
<td>0.002</td>
<td>-0.7 to 0.7</td>
<td>1.0</td>
<td>-0.05</td>
<td>-0.7 to 0.6</td>
</tr>
<tr>
<td>BMI Z-score (1 = low, 5 = high)</td>
<td>0.7</td>
<td>0.4 to 1.1</td>
<td>&lt;0.0001</td>
<td>0.3</td>
<td>-0.06 to 0.7</td>
<td>0.09</td>
<td>-0.2</td>
<td>-0.2 to 0.6</td>
</tr>
<tr>
<td>Tanner stage</td>
<td>-0.2</td>
<td>-1.0 to 0.6</td>
<td>0.6</td>
<td>0.4</td>
<td>-0.5 to 1.3</td>
<td>0.4</td>
<td>0.3</td>
<td>-0.7 to 1.2</td>
</tr>
<tr>
<td>Age at blocker placement, years</td>
<td>0.06</td>
<td>-0.3 to 0.4</td>
<td>0.7</td>
<td>-0.1</td>
<td>-0.5 to 0.3</td>
<td>0.6</td>
<td>-0.5</td>
<td>-0.9 to 0.002</td>
</tr>
<tr>
<td>Daily calcium intake, mg/d</td>
<td>0.0003</td>
<td>-0.0008 to 0.001</td>
<td>0.6</td>
<td>-0.0003</td>
<td>-0.001 to 0.001</td>
<td>1.0</td>
<td>-0.001</td>
<td>-0.003 to 0.0006</td>
</tr>
<tr>
<td>Serum 25-OH D, ng/mL</td>
<td>-0.0007</td>
<td>-0.04 to 0.03</td>
<td>1.0</td>
<td>0.001</td>
<td>-0.02 to 0.05</td>
<td>0.4</td>
<td>0.04</td>
<td>0.0006 to 0.08</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Predictors of vBMD Z-scores</th>
<th>TBD</th>
<th></th>
<th>CBD</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>(Constant)</td>
<td>-1.2</td>
<td>21.2 to 18.8</td>
<td>0.9</td>
<td>-0.09</td>
</tr>
<tr>
<td>Female sex designated at birth</td>
<td>-0.2</td>
<td>-6.6 to 6.1</td>
<td>0.9</td>
<td>2.0</td>
</tr>
<tr>
<td>PAQ-C score (1 = low, 5 = high)</td>
<td>0.1</td>
<td>-4.1 to 4.4</td>
<td>0.9</td>
<td>0.2</td>
</tr>
<tr>
<td>BMI Z-score</td>
<td>-0.5</td>
<td>-3.1 to 2.1</td>
<td>0.6</td>
<td>-0.06</td>
</tr>
<tr>
<td>Tanner stage</td>
<td>1.2</td>
<td>-4.0 to 6.5</td>
<td>0.5</td>
<td>0.8</td>
</tr>
<tr>
<td>Age at blocker placement, y</td>
<td>-0.06</td>
<td>-1.4 to 1.2</td>
<td>0.9</td>
<td>-0.2</td>
</tr>
<tr>
<td>Daily calcium intake, mg/d</td>
<td>-0.001</td>
<td>-0.005 to 0.003</td>
<td>0.5</td>
<td>-0.0009</td>
</tr>
<tr>
<td>Serum 25-OH D, ng/mL</td>
<td>-0.04</td>
<td>-0.4 to 0.3</td>
<td>0.7</td>
<td>-0.06</td>
</tr>
</tbody>
</table>

Abbreviations: aBMD, areal bone mineral density; BMD, bone mineral density; BMI, body mass index; CI, confidence interval; PAQ-C, Physical Activity Questionnaire for Older Children; vBMD, volumetric bone mineral density.
trabecular bone. The hip mineralizes earlier than the spine [30], such that we may be able to observe differences at the hip before they are apparent in other regions. The hip is also a weight-bearing site, and the lower BMD Z-scores in the DMAB youth make sense given the findings of lower PAQ-C scores in the DMAB youth. Finally, the International Society for Clinical Densitometry does suggest potential utility in proximal femur DXA measurements for assessing children with reduced weight-bearing of the lower extremities who would benefit from serial DXA measurements into adulthood [29].

With respect to determinants of skeletal health, PAQ-C scores were low overall and significantly lower in DMAB than DFAB youth, providing a potential explanation for the lower pretreatment BMD Z-scores in the DMAB group. However, regression models showed that PAQ-C scores could not completely account for these differences, suggesting that other factors may also contribute to this difference. Further reinforcing the postulation that lower physical activity contributes to the low BMD Z-scores are the statistically significantly lower PAQ-C scores in the group with low BMD when compared with the group with normal BMD. Prior studies according to recorded sex (gender identity was not ascertained) have reported that boys have higher PAQ-C scores than girls [21, 22]; thus, TGD youth in our study tended to have physical activity levels that correspond to gender identity.

In contrast to physical activity, no significant differences were found in serum 25-hydroxyvitamin D, dietary calcium intake, and BMI Z-scores between DFAB and DMAB groups, or between low-BMD and normal-BMD groups. However, daily calcium intake was globally suboptimal in our early-pubertal TGD youth cohort. The majority of the literature supports adequate calcium intake in improving BMD [28], with greater gains seen in those who begin supplementation at earlier stages of puberty [31] and who have lower baseline daily calcium intake [32]. However, there are still gains seen in those who are later in puberty and have higher baseline daily calcium intakes [33]. These results suggest that potential interventions for improving BMD could include standard recommendations for optimizing dietary calcium and vitamin D intake as well as increasing weight-bearing exercise, which could be initiated in the prepubertal to early-pubertal time period [34-36]. Additionally, BMI Z-scores were a significant positive predictor of BMD Z-scores at the TBLH site, reinforcing that careful assessment of physical activity and dietary history to screen for eating disorders should be done [37], particularly if low BMD is found.

Strengths of our study include assessments of dietary calcium intake, physical activity, and vitamin D status, which have not been reported previously in transgender youth. A limitation of this study is related to the observational and multisite nature of the Trans Youth Care study, such that BMD measurements were not standardized across all sites. Despite this limitation, we obtained comparable results across the different imaging modalities, lending robustness to our findings. As of yet, fracture data have not been reported in transgender adolescents and, thus, BMD Z-scores are the only current proxy for estimating future fracture risk.

It has been shown that significant bone mineralization occurs after linear growth is complete [30]. Because timing of puberty influences peak bone mineral content, such that later pubertal onset leads to lower adult bone mineral content [38-40], longitudinal follow-up of this cohort with continued skeletal imaging will be critical for understanding the trajectory of bone mineral accrual as these youth are treated with GnRHa and progress to treatment with gender-affirming sex steroids. Findings from this pretreatment analysis will be followed up by longitudinal assessments over time and will further inform our current treatment and monitoring protocols.

Acknowledgments

We thank all the study participants and their families for participating in the Trans Youth Care Study, as well as the clinical research coordinators. We thank Bo Fan, MD, and Ellen Fung, PhD, RD, CCD, for their invaluable advice regarding analysis of the bone density measurements.

Financial Support: Research reported in this publication was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of
Health (award numbers R01HD082554 and F32HD098763). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Additional Information

Correspondence: Janet Y. Lee, MD, MPH, MAS, UCSF, Global Health & Clinical Sciences, Mission Hall, 550 16th Street, 4th Floor, Box 0434, San Francisco, CA 94143, USA. E-mail: janet.lee@ucsf.edu.

Disclosures Summary: J.Y.L., C.F., J.O.-K., R.G., and D.V.G. have no relevant financial interests to disclose. Y.-M.C. and S.M.R. have served on an advisory board for Endo Pharmaceuticals.

Data Availability: Restrictions apply to the availability of data generated or analyzed during this study to preserve patient confidentiality or because they were used under license. The corresponding author will on request detail the restrictions and any conditions under which access to some data may be provided.

References and Notes


